(Q39182553)

English

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib

scientific article published on 12 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 September 2017

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib (English)

1 reference

Europe PubMed Central

9 September 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Annemilaï Tijeras-Raballand

3

object named as

Annemilaï Tijeras-Raballand

0 references

author name string

Maria Serova

1

1 reference

Europe PubMed Central

9 September 2017

Armand de Gramont

2

1 reference

Europe PubMed Central

9 September 2017

Annemilaï Tijeras-Raballand

3

1 reference

Europe PubMed Central

9 September 2017

Célia Dos Santos

4

1 reference

Europe PubMed Central

9 September 2017

Maria Eugenia Riveiro

5

1 reference

Europe PubMed Central

9 September 2017

Khemaies Slimane

6

1 reference

Europe PubMed Central

9 September 2017

Sandrine Faivre

7

1 reference

Europe PubMed Central

9 September 2017

Eric Raymond

8

1 reference

Europe PubMed Central

9 September 2017

publication date

12 March 2013

1 reference

Europe PubMed Central

9 September 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

9 September 2017

71

1 reference

Europe PubMed Central

9 September 2017

1297-1307

1 reference

Europe PubMed Central

9 September 2017

5

1 reference

Europe PubMed Central

9 September 2017

https://scigraph.springernature.com/pub.10.1007/s00280-013-2129-6

0 references

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Targeting the mTOR signaling network for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Current development of mTOR inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

EAU guidelines on renal cell carcinoma: the 2010 update

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

EORTC-GU group expert opinion on metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Targeting mTOR pathways in human malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2129-6

21 January 2018

Identifiers

10.1007/S00280-013-2129-6

1 reference

Europe PubMed Central

9 September 2017

1 reference

Europe PubMed Central

9 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39182553&oldid=1811939793"